CASI News and Press, CASI Pharmaceuticals Inc. From 12/10/21

LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the Center for D...

CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE CTA APPROVAL FOR CLINICAL STUDY OF BI-1206 IN NHL IN CHINA ~ NMPA approved BI-1206 CTA a novel anti-FcγRIIB ~~ Trials Expected to Enroll Patients starting in 1H 2022 PR Newswire ROCKVILLE, Md. and BEIJING ...

Rockville, Maryland-based CASI Pharmaceuticals (NASDAQ:CASI) has added ~11.6% in the pre-market on below-average volume after its CEO Wei-Wu He disclosed the purchase of 400K company shares. About 456.7K CASI (CASI) shares have changed hands so far, compared to the 65-day average vo...

CASI Pharmaceuticals To Present At Jefferies London Healthcare Conference PR Newswire ROCKVILLE, Md. , and BEIJING , Nov. 15, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and comme...

CASI Pharmaceuticals, Inc. (CASI) Q3 2021 Earnings Conference Call November 12, 2021, 08:00 ET Company Participants Jacob Moshel - IR Wei-Wu He - Chairman & CEO Alexander Zukiwski - Chief Medical Officer Wong Hu - Former COO, General Counsel & Secretary Conference Call Participants Le...

CASI Pharmaceuticals (NASDAQ:CASI): Q3 GAAP EPS of -$0.07 misses by $0.01. Revenue of $8.11M (+91.3% Y/Y) beats by $0.58M. Press Release As of September 30, 2021, CASI had cash and cash equivalents of $53.1M compared to $57.1M as of December 31, 2020. For further details see: CASI Pharm...

CASI Pharmaceuticals Announces Third Quarter 2021 Financial Results -EVOMELA Third Quarter 2021 Revenue Continues Strong Upward Trend - - Additional Positive Clinical Data on BI-1206 - - Partner Juventas completed Series C financing round RMB410 million (approximately $6...

CASI Pharmaceuticals (NASDAQ:CASI) is scheduled to announce Q3 earnings results on Friday, November 12th, before market open. The consensus EPS Estimate is -$0.06 (+57.1% Y/Y) and the consensus Revenue Estimate is $7.53M (+77.6% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward r...

AZN, BKKT, BKSY, BPTH, CAAS, CASI, OTCQX:CCHWF, CGEN, OTCQX:DTEGF, EMAN, GP, OTCPK:HNHAF, HYZN, ITRM, MIR, MOTS, NGD, NXTD, PX, SOHO, SPB, STRR, OTCPK:TOSBF, VERO, OTCPK:VITFF, VIVO For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earn...

CASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On BI-1206 At ASH 2021 ~ BI-1206 restores rituximab activity in relapsed or refractory patients ~~ Demonstrates ORR 50%, DCR 58%, with complete responses lasting beyond 18 and 24 months PR...